Search academic texts

Information × Registration Number 0216U005326, 0115U003003 , R & D reports Title Choosing the tactics of treatment of bone metastases with 153 Sm-oxabifore for reducing of the complication risk popup.stage_title Head Grushka G.V., Registration Date 07-07-2016 Organization Grigor'ev Institut for Medical Radiology popup.description2 The object of study: a toxic effect of radionuclide therapy, clinical, laboratory and morphological properties. The purpose of study: to improve the efficiency of radionuclide therapy of bone metastases by reducing the frequency and extent of complications by individualizing the selection regimen. Research methods and equipment: clinical, laboratory (determination of the level of white blood cells, hemoglobin, platelets, granulocytes), radiation, radionuclide 99 mТс-Pyrphotech and 153Sm-oksabifor and statistical studies. Equipment: Gamma Camera, X-ray machine, CT scanner, an automatic analyzer. Theoretical and practical results: for cancer patients with bone metastases have determined the nature and frequency of complications; the risks of violation of hematopoiesis after radionuclide therapy with 153Sm-oksabifor. The relationship between the degree of manifestation of complications radionuclide therapy with 153Sm-oksabifor and previous anticancer treatment was found. The presence of hematological toxic effect of a temporary nature after radionuclide therapy was detected. Informative indicators of the toxic effect of 153Sm-oksabifor are morphofunctional condition of the bone marrow and peripheral blood. It was established trend of influence increased activity of 153Sm-oksabifor to reduce the level of hemoglobin, white blood cell count, granulocytes and platelets. Recency: for the first time it found that "positive" bone scan with 99 mТс-Pyrphotech and index retained activity of 153Sm-oksabifor - are predictive indicators of efficiency radionuclide therapy and are promising for monitoring patients with bone metastases. The effectiveness of the implementation: evaluation of prognostic indicators of risk hematopoietic disorders will increase the efficiency of radionuclide therapy of bone metastases by reducing the frequency and extent of complications by individualizing treatment. Scope: radiology, oncology. Product Description popup.authors Аверьянова Л.О. Аврунін О.Г. Астап’єва О.М. Боброва В.М. Грушка Г.В. Зінвалюк О.В. Зац О.С. Кобзар Т.І. Коломацька В.В. Луховицька Н.І. Насонова А.М. Підченко Н.С. Павліченко Ю.В. Паскевич О.І. Поповська Т.М. Ріяко В.М. Ревенкова С.І. Савченко А.С. Стадник Л.Л. Тихоліз О.М. Ткаченко Г.І. Ткаченко Ю.Г. Черкаско Л.В. popup.nrat_date 2020-04-02 Close